EICHOR
● Completed
A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)
Condition: Lymphoma · Sponsor: Incyte Corporation
About this study
The purpose of this study is to evaluate the safety and efficacy of two parsaclisib treatment regimens in participants diagnosed with relapsed or refractory marginal zone lymphoma (MZL) who are naive to or were previously treated with a Bruton's tyrosine kinase (BTK) inhibitor.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (86)
| University of Alabama At Birmingham Comprehensive Cancer Center | Birmingham, Alabama, United States | — |
| Arizona Oncology Associates | Tempe, Arizona, United States | — |
| Torrance Health Association | Redondo Beach, California, United States | — |
| Sansum Clinic | Santa Barbara, California, United States | — |
| Central Coast Medical Oncology | Santa Maria, California, United States | — |
| UCLA Healthcare Hematology-Oncology | Santa Monica, California, United States | — |
| St. Joseph Heritage Healthcare | Santa Rosa, California, United States | — |
| Innovative Clinical Research Institute | Whittier, California, United States | — |
| Loyola University Medical Center | Whittier, California, United States | — |
| Valley View Hospital | Glenwood Springs, Colorado, United States | — |
| St. Mary'S Hospital Regional Cancer Center | Grand Junction, Colorado, United States | — |
| University of Miami Sylvester Comprehensive Cancer Center | Miami, Florida, United States | — |
+ 74 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03144674